2025, Kitagaki H, Takeda K, Murai K, Maeda H. Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments. Clin Pharmacol Ther. 2025 May 20. doi: 10.1002/cpt.3722.
業績
2025, Kitagaki H, Takeda K, Murai K, Maeda H. Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments. Clin Pharmacol Ther. 2025 May 20. doi: 10.1002/cpt.3722.
